<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-147468" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Beryllium Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stearney</surname>
            <given-names>Elaine R.</given-names>
          </name>
          <aff>Marietta Memorial Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jakubowski</surname>
            <given-names>Julian A.</given-names>
          </name>
          <aff>Marietta Memorial Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Regina</surname>
            <given-names>Angela C.</given-names>
          </name>
          <aff>St. Barnabas Health System</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Elaine Stearney declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Julian Jakubowski declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Angela Regina declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-147468.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Beryllium is a light grey alkaline earth metal found naturally in the environment. Beryllium is released into the environment primarily during the combustion of fossil fuels, although it has applications in a wide variety of technological fields. Beryllium exposure and toxicity can cause serious acute and long-term health effects, making its immediate identification and treatment crucial. Beryllium exposure has been linked to workers in the nuclear, defense, electronics, biomedical, and semiconductor industries. This activity reviews the evaluation, treatment, and management of patients with acute beryllium toxicity and chronic beryllium disease and highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the risk factors associated with beryllium exposure and developing chronic beryllium disease.</p></list-item><list-item><p>Describe the pathophysiology of acute beryllium toxicity and chronic beryllium disease.</p></list-item><list-item><p>Outline the typical presentation of a patient with acute beryllium toxicity and chronic beryllium disease.</p></list-item><list-item><p>Summarize the recommended treatment and management of acute beryllium toxicity and chronic beryllium disease.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=147468&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=147468">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-147468.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Beryllium is the fourth element in the periodic table and is a light, brittle, and gray alkaline earth metal. Beryllium is found naturally in coal, rocks, dust, and soil and is typically bonded with other elements. It is released into the environment through dust, airborne particles, and the combustion of fossil fuels. Because of its high melting point, strength, and lightweight nature, it is commonly used in aerospace materials, electronics, defense technologies, X-ray equipment, and as an alloying element in conjunction with other metals such as copper, iron, or nickel.&#x000a0;</p>
        <p>The general public can be exposed through waterways, food, air,&#x000a0;and accidental soil contact or ingestion. However, most beryllium exposure and resulting beryllium toxicity result from occupational exposure via inhalation, resulting in pulmonary disease.&#x000a0;</p>
        <p>Acute beryllium toxicity, an acute chemical pneumonitis, has been reported after high-intensity exposures. Cases have become rare after increased government regulations were set into place.</p>
        <p>Chronic beryllium disease, also known as berylliosis, is a pulmonary granulomatous disease that occurs in sensitized individuals. It is mediated via a type IV hypersensitivity reaction.</p>
      </sec>
      <sec id="article-147468.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Beryllium is a naturally occurring element typically distributed in soil and volcanic dust.<xref ref-type="bibr" rid="article-147468.r1">[1]</xref>&#x000a0;Beryllium is released into the environment through natural processes such as weathering or volcanic activity and artificially through processes such as mining and combustion. It was first identified as a health hazard in the 1930s, and its acute and chronic&#x000a0;toxic manifestations&#x000a0;were discovered first in workers at a fluorescent lamp manufacturing plant.<xref ref-type="bibr" rid="article-147468.r2">[2]</xref>&#x000a0;</p>
        <p>Beryllium exposure has since been linked to workers in nuclear, defense, electronics, biomedical, and semiconductor industries, with the number of exposed US workers ranging from 21,200 to 800,000 between the 1970s and 1980s.<xref ref-type="bibr" rid="article-147468.r3">[3]</xref>&#x000a0;Clusters of berylliosis have also been linked to concrete dust exposure&#x000a0;and beryllium manufacturing plants.<xref ref-type="bibr" rid="article-147468.r4">[4]</xref><xref ref-type="bibr" rid="article-147468.r5">[5]</xref></p>
        <p>Beryllium is typically used in industry as either a pure metal, beryllium oxide, or alloy. Beryllium oxide, in particular, is known for having a high heat capacity and is used primarily in select electronic equipment.<xref ref-type="bibr" rid="article-147468.r6">[6]</xref>&#x000a0;Beryllium alloys can be divided into two categories: high beryllium content (up to 30% beryllium) and low beryllium content (2 to 3% beryllium).<bold>&#x000a0;</bold>Beryllium alloys are involved in the&#x000a0;manufacture of cars, computers, sports equipment, and dental bridges.&#x000a0;</p>
        <p>Acute beryllium pneumonitis occurs after high-intensity exposure and results from respiratory tract inflammation. Depending on the solubility of the beryllium compound, both upper and lower respiratory inflammation can be seen, and this is not specific to beryllium. Due to increased workplace safety initiatives, acute beryllium toxicity has become rare after the 1980s.&#x000a0;</p>
        <p>A patient must become sensitized to beryllium to develop chronic beryllium disease via a cell-mediated type IV hypersensitivity mechanism. Patients with a specific HLA-DPB1-Glu polymorphism are more susceptible to beryllium sensitization. Beryllium-specific CD4+ T cells, in turn, recognize beryllium and induce proliferation. The release of various inflammatory cytokines results in granuloma formation and is histologically indistinguishable from sarcoidosis.</p>
      </sec>
      <sec id="article-147468.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Occupational exposure to beryllium and other metals is a health risk to workers worldwide. Increased regulations&#x000a0;such as limiting the permissible exposure limit (PEL) of beryllium in US workers, enforced by governing bodies such as the Occupational Safety and Health Administration (OSHA), have made acute beryllium pneumonitis rare. But, despite this increase in safety, the mortality from tracheal, bronchial, and lung cancer resulting from general, occupational carcinogen exposure has increased globally from 1990&#x000a0;to 2019.<xref ref-type="bibr" rid="article-147468.r7">[7]</xref>&#x000a0;The International Agency for Research on Cancer has classified beryllium as a Class I human carcinogen.<xref ref-type="bibr" rid="article-147468.r8">[8]</xref></p>
        <p>One study found that the standardized mortality ratio for berylliosis in workers involved in nuclear weapons research&#x000a0;was significantly elevated.<xref ref-type="bibr" rid="article-147468.r9">[9]</xref>&#x000a0;Because beryllium sensitivity and chronic beryllium disease only occur in individuals exposed to beryllium,&#x000a0;men are more predisposed to developing these conditions secondary to work practices.&#x000a0;Family members of those working with beryllium are also at risk of exposure, and vehicles owned and used by machinists in this industry were contaminated with beryllium.<xref ref-type="bibr" rid="article-147468.r10">[10]</xref>&#x000a0;</p>
        <p>While beryllium toxicity is more commonly due to occupational exposure, the general public also has exposure risk.&#x000a0;Beryllium can be&#x000a0;present in small amounts in contaminated soil, air, food, or water. Individuals who live near waste disposal sites, in particular, may be at increased risk for beryllium exposure through the soil.<xref ref-type="bibr" rid="article-147468.r11">[11]</xref>&#x000a0;Although beryllium can be released into waterways through weathering, volcanic activity, or artificial processes, it is typically bound to sediment in this setting and is generally immobile.</p>
      </sec>
      <sec id="article-147468.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Acute</bold>
</p>
        <p>Acute beryllium exposure, typically via inhalation, can cause&#x000a0;a diffuse inflammatory response involving the upper and lower airway. Acute beryllium disease&#x000a0;is similar to other cases of chemical pneumonitis, and symptoms depend on the compound's solubility.<xref ref-type="bibr" rid="article-147468.r12">[12]</xref> This inflammation commonly results in bronchiolitis, pulmonary edema, and pneumonitis. Skin contact with beryllium can also cause dermatologic inflammation resulting in irritation, ulceration, and subcutaneous granulomas.</p>
        <p>
<bold>Chronic</bold>
</p>
        <p>Chronic beryllium disease (CBD), or berylliosis, is a granulomatous lung disease that results from beryllium exposure and sensitization and is due to an antigen-specific, cell-mediated immune response.<xref ref-type="bibr" rid="article-147468.r13">[13]</xref><xref ref-type="bibr" rid="article-147468.r14">[14]</xref><xref ref-type="bibr" rid="article-147468.r15">[15]</xref>&#x000a0;Research suggests the degree of immune response may be genetic and is associated with HLA DPB-1 E69 genotypes.<xref ref-type="bibr" rid="article-147468.r16">[16]</xref><xref ref-type="bibr" rid="article-147468.r17">[17]</xref>&#x000a0;</p>
        <p>It is clinically indistinguishable from sarcoidosis and causes noncaseating granulomas in lung tissue and thoracic lymph nodes.<xref ref-type="bibr" rid="article-147468.r17">[17]</xref><bold>&#x000a0;</bold>Chronic beryllium disease can remain stable for many years but rarely progresses into pulmonary fibrosis and is associated with an increased risk of lung cancer.</p>
      </sec>
      <sec id="article-147468.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>In chronic beryllium disease, epithelioid noncaseating granulomatous inflammation will be present on lung biopsy. These pathognomonic lesions are indistinguishable from those of sarcoidosis.<xref ref-type="bibr" rid="article-147468.r18">[18]</xref> In one case study, bronchoalveolar lavage performed on two beryllium production facility workers revealed lymphocytic alveolitis.<xref ref-type="bibr" rid="article-147468.r12">[12]</xref></p>
      </sec>
      <sec id="article-147468.s7" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Acute beryllium disease&#x000a0;presents similar to other cases of chemical pneumonitis, and symptoms depend on the compound's solubility.<xref ref-type="bibr" rid="article-147468.r12">[12]</xref> Sensitization and chronic disease occur in genetically susceptible people and commonly occur via inhalational exposure. Acute beryllium toxicity is a risk for chronic beryllium disease, and 17% of patients with acute toxicity will develop CBD.<xref ref-type="bibr" rid="article-147468.r19">[19]</xref>&#x000a0;</p>
        <p>Sensitization (not acute toxicity) precedes the development of CBD, and of those sensitized, 31% progressed to chronic beryllium disease.<xref ref-type="bibr" rid="article-147468.r20">[20]</xref>&#x000a0;Chronic beryllium disease is a granulomatous lung disease that results from beryllium exposure and sensitization and&#x000a0;is due to an antigen-specific, cell-mediated immune response.<xref ref-type="bibr" rid="article-147468.r13">[13]</xref><xref ref-type="bibr" rid="article-147468.r14">[14]</xref><xref ref-type="bibr" rid="article-147468.r15">[15]</xref>&#x000a0;</p>
        <p>Inhalation of beryllium salts disrupts the capillary-alveolar membrane and causes epithelial cell membrane disruption, presenting an opportunity for antigen and antigen-presenting-cell (APC) interaction.<xref ref-type="bibr" rid="article-147468.r21">[21]</xref>&#x000a0;Helper-T cells seem to be the primary lymphocyte population involved in the early immune response to beryllium salts,&#x000a0;followed by sustained cytokine production, particularly TNF-&#x003b1; and IL-6.<xref ref-type="bibr" rid="article-147468.r22">[22]</xref>&#x000a0;</p>
        <p>Research has shown that macrophages attracted to the site of inflammation can phagocytose beryllium, which will lead to lymphocyte proliferation.<xref ref-type="bibr" rid="article-147468.r23">[23]</xref>&#x000a0;Approximately 80% of patients diagnosed with beryllium sensitivity or chronic beryllium disease possess an HLA-DPB1 glu69 polymorphism, suggesting that the density of these molecules on an antigen-presenting cell may affect disease development and progression.<xref ref-type="bibr" rid="article-147468.r24">[24]</xref><xref ref-type="bibr" rid="article-147468.r25">[25]</xref>&#x000a0;</p>
        <p>Because of this genetic predisposition, there is no classical dose-response relationship between the level of beryllium exposure and the severity of symptoms or disease progression.</p>
      </sec>
      <sec id="article-147468.s8" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Acute beryllium sensitivity and Berylliosis should be suspected in any patient presenting with respiratory complaints alongside known or suspected beryllium exposure.&#x000a0;Acute beryllium toxicity will typically occur after exposure levels of 25 to 100 &#x003bc;g/m. It will typically manifest with inflammation of the upper and lower respiratory tract, similar to other cases of chemical pneumonitis.<xref ref-type="bibr" rid="article-147468.r26">[26]</xref>&#x000a0;</p>
        <p>People with acute beryllium toxicity may present with cough, shortness of breath, fatigue, chest pain, hemoptysis, palpitations, decreased appetite, or fever. Beryllium sensitivity can develop after initial exposure, and those who are sensitized can be asymptomatic.</p>
        <p>Skin manifestations of beryllium exposure include dermatitis, beryllium ulcers, and dermal granulomas. Chronic, non-healing ulcers may result from beryllium implantation into an abrasion or laceration in the skin, with excision required for treatment.<xref ref-type="bibr" rid="article-147468.r27">[27]</xref><xref ref-type="bibr" rid="article-147468.r28">[28]</xref>&#x000a0;Small granulomatous nodules often are found on the hands, arms, and chest.&#x000a0;</p>
        <p>The most common complaints of patients presenting with chronic beryllium disease are dyspnea with exertion, dry cough, unintended weight loss, night sweats, and fatigue.<xref ref-type="bibr" rid="article-147468.r29">[29]</xref>&#x000a0;For both acute and chronic beryllium toxicity, initial treatment involves immediate removal from the source of exposure. Beryllium sensitization can be confirmed with a positive beryllium lymphocyte proliferation test (BeLPT), which is further discussed in the&#x000a0;evaluation portion of this article.<xref ref-type="bibr" rid="article-147468.r30">[30]</xref></p>
      </sec>
      <sec id="article-147468.s9" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Acute findings of beryllium&#x000a0;toxicity on chest X-ray may initially be normal, followed by diffuse alveolar infiltrates 1&#x000a0;to 3 weeks after initial exposure.<xref ref-type="bibr" rid="article-147468.r31">[31]</xref>&#x000a0;Patients with beryllium sensitivity have normal lung physiology and typically only have an abnormal BeLPT. Early pulmonary function testing may only have isolated abnormalities of the diffusing capacity. Patients will develop restrictive, obstructive, and/or gas exchange abnormalities as the disease progresses.<xref ref-type="bibr" rid="article-147468.r18">[18]</xref>&#x000a0;Patients with advanced chronic disease will usually have a restrictive pattern with fibrosis.&#x000a0;</p>
        <p>The chest x-ray findings of chronic beryllium disease are nonspecific and similar to those of sarcoidosis. Ill-defined nodular or irregular opacities and hilar adenopathy can be seen. The abnormalities often may only be present in the upper lobes. With more advanced disease, fibrosis&#x000a0;and the development of blebs and emphysema in adjacent areas can be seen. Radiographic abnormalities will sometimes improve with the removal of the offending agent and initiation of corticosteroids but will typically never fully resolve.<xref ref-type="bibr" rid="article-147468.r29">[29]</xref></p>
        <p>Chronic beryllium disease has a latency period and is usually identified 10 to 20 years after initial exposure but can develop up to 40 years after initial exposure.<xref ref-type="bibr" rid="article-147468.r32">[32]</xref>&#x000a0;Chronic beryllium disease presents very similarly to pulmonary sarcoidosis and should be suspected in individuals presenting with known sarcoidosis or poor pulmonary function with previous exposure to beryllium. Diagnosis of chronic beryllium disease can be suggested via in-vitro lymphocyte proliferation testing that results in a cell-mediated immune response to beryllium, known as the beryllium lymphocyte proliferation test (BeLPT) or in-vivo patch-testing.<xref ref-type="bibr" rid="article-147468.r18">[18]</xref>&#x000a0;</p>
        <p>In addition to the BeLPT, tissue confirmation via biopsy should be performed. As a result of the development of these tests, many workers are now screened for beryllium sensitivity and chronic beryllium disease before developing symptoms, leading to early intervention and treatment.&#x000a0;</p>
        <p>
<bold>Sarcoidosis vs. Berylliosis</bold>
</p>
        <p>While pulmonary manifestations of these two diseases are nearly identical clinically, chronic beryllium disease typically lacks the extrapulmonary findings common in sarcoidosis. Cystic bone lesions, ocular involvement, neurosarcoidosis, cardiac disease, parotitis, and salivary gland involvement are all significant findings in sarcoidosis but not chronic beryllium disease.<xref ref-type="bibr" rid="article-147468.r18">[18]</xref>&#x000a0;Acute conjunctivitis may result from ocular exposure to beryllium salts but is not a finding in chronic beryllium disease.<xref ref-type="bibr" rid="article-147468.r33">[33]</xref></p>
      </sec>
      <sec id="article-147468.s10" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of acute beryllium exposure and sensitivity primarily involves removal from the source of exposure and symptomatic treatment alongside stabilization of any abnormal vital signs. Inhaled corticosteroids and short-acting bronchodilators can be used for symptomatic relief. Corticosteroids are the primary treatment of chronic beryllium disease, and many patients will see symptomatic improvement with steroid administration. Primary treatment is typically prednisone 40mg daily or every other day, with the response to therapy assessed every 3 to 6 months both clinically and radiographically. The prednisone dose can be reduced based on improvement in symptoms, CT findings of inflammation/fibrosis, and PFT results.<xref ref-type="bibr" rid="article-147468.r34">[34]</xref>&#x000a0;</p>
        <p>Despite early identification and treatment, progressive decline in pulmonary function and fibrosis is possible even in individuals who receive continued immunosuppressive therapy.<xref ref-type="bibr" rid="article-147468.r29">[29]</xref>&#x000a0;Over time and as the disease progresses, relapses and worsening pulmonary function are common and may require a transition to lifelong immunosuppressant treatment.<xref ref-type="bibr" rid="article-147468.r35">[35]</xref>&#x000a0;</p>
        <p>Due to the significant potential for side effects associated with long-term steroid use, the use of steroid-sparing therapies (e.g., methotrexate, azathioprine, or infliximab) may be considered in patients experiencing notable side effects.<xref ref-type="bibr" rid="article-147468.r34">[34]</xref></p>
      </sec>
      <sec id="article-147468.s11" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Acute and chronic beryllium toxicity presents very similarly to other respiratory diseases, including but not limited to the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pulmonary edema</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Asthma&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Pulmonary embolism</p>
          </list-item>
          <list-item>
            <p>Pneumonia</p>
          </list-item>
          <list-item>
            <p>Chemical pneumonitis</p>
          </list-item>
          <list-item>
            <p>Pulmonary sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Idiopathic pulmonary fibrosis</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Heavy metal diseases</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-147468.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Prognosis is highly variable and is dependent on the duration of exposure, exposure levels, and genetic susceptibility. Many patients who develop beryllium sensitivity will not go on to develop chronic beryllium disease and may only require short-term treatment and monitoring. The course of illness may be self-limiting and mild but can also rapidly progress, involving death in approximately 10% of cases.<xref ref-type="bibr" rid="article-147468.r31">[31]</xref>&#x000a0;Research on cases in the 1940s and 1950s suggested mortality may be as high as 30%, but with advancements in monitoring and treatment, the mortality rate today is not certain.<xref ref-type="bibr" rid="article-147468.r29">[29]</xref></p>
      </sec>
      <sec id="article-147468.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Acute complications of beryllium sensitivity include pulmonary edema and cor pulmonale.<xref ref-type="bibr" rid="article-147468.r36">[36]</xref><xref ref-type="bibr" rid="article-147468.r37">[37]</xref>&#x000a0;Patients with chronic beryllium disease can develop granulomatous hepatitis and chronic interstitial nephritis due to the persistent inflammatory response produced by the body. Patients who require chronic steroid use are also at risk of developing complications from their treatment, such as hyperglycemia, osteoporosis, weight gain, and increased risk of infection.</p>
      </sec>
      <sec id="article-147468.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Occupational health professionals should continuously monitor patients suspected of chronic beryllium disease.</p>
      </sec>
      <sec id="article-147468.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Beryllium is a naturally-found alkaline earth metal and can be released from the Earth's crust into the air and waterways. Individuals working in certain fields, such as nuclear, defense, electronics, biomedical, and semiconductor industries, are at higher risk for occupational exposure and subsequent disease development.</p>
        <p>Beryllium is toxic as both a skin irritant and an inhaled substance and can result in dermatitis, acute pneumonitis, and chronic pulmonary disease. The first signs of serious or life-threatening acute beryllium exposure may involve difficulty breathing, chest pain, or shortness of breath.&#x000a0;Despite increasing governmental regulations&#x000a0;limiting exposure to beryllium in high-risk occupations, any amount of beryllium can cause short-term and long-term diseases.&#x000a0;</p>
        <p>In cases of suspected beryllium poisoning with acute symptoms, such as difficulty breathing or chest pain, transfer to the nearest emergency department.</p>
        <p>The Poison Control Center may be contacted for further recommendations.</p>
        <p>If there is concern about a hazardous amount of occupational beryllium exposure, the Occupational Safety and Health Administration (OSHA) may be contacted for further investigation.</p>
      </sec>
      <sec id="article-147468.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Early identification of beryllium toxicity is crucial and will allow for early treatment and monitoring of disease progression. An interprofessional team-based approach between all staff members is required to ensure proper communication, identification, and treatment of this disease. Extra care should be taken to ensure&#x000a0;pulmonary and cardiac stability in acute cases. This will require cooperation between nursing staff, respiratory technicians, primary care physicians, toxicologists, and pulmonary/critical care specialists. Collaborative work between each team member is imperative and will ensure improved patient outcomes. [Level 4]</p>
      </sec>
      <sec id="article-147468.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=147468&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=147468">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/lung-disease-respiratory-health/beryllium-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=147468">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/147468/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=147468">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-147468.s18">
        <title>References</title>
        <ref id="article-147468.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dawood</surname>
                <given-names>AMA</given-names>
              </name>
              <name>
                <surname>Glover</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Akortia</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nyarku</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Essel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sarfo</surname>
                <given-names>EO</given-names>
              </name>
              <name>
                <surname>Ameho</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Aberikae</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Environmental radiation and health risk assessment in the neighborhood of a radioactive waste management facility.</article-title>
            <source>Environ Monit Assess</source>
            <year>2022</year>
            <month>Mar</month>
            <day>30</day>
            <volume>194</volume>
            <issue>4</issue>
            <fpage>314</fpage>
            <pub-id pub-id-type="pmid">35355157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Beryllium: a modern industrial hazard.</article-title>
            <source>Annu Rev Public Health</source>
            <year>2007</year>
            <volume>28</volume>
            <fpage>259</fpage>
            <page-range>259-77</page-range>
            <pub-id pub-id-type="pmid">17094767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Henneberger</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Goe</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Doney</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Groce</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Industries in the United States with airborne beryllium exposure and estimates of the number of current workers potentially exposed.</article-title>
            <source>J Occup Environ Hyg</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>1</volume>
            <issue>10</issue>
            <fpage>648</fpage>
            <page-range>648-59</page-range>
            <pub-id pub-id-type="pmid">15631056</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frye</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Quartucci</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rakete</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grubanovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>H&#x000f6;hne</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mangold</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gier&#x000e9;</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Quernheim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zissel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust.</article-title>
            <source>Chest</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>159</volume>
            <issue>3</issue>
            <fpage>1084</fpage>
            <page-range>1084-1093</page-range>
            <pub-id pub-id-type="pmid">32926872</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Virji</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Cox-Ganser</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stanton</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stefaniak</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Associations of Metrics of Peak Inhalation Exposure and Skin Exposure Indices With Beryllium Sensitization at a Beryllium Manufacturing Facility.</article-title>
            <source>Ann Work Expo Health</source>
            <year>2019</year>
            <month>Oct</month>
            <day>11</day>
            <volume>63</volume>
            <issue>8</issue>
            <fpage>856</fpage>
            <page-range>856-869</page-range>
            <pub-id pub-id-type="pmid">31504146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Electronic and thermal properties of monolayer beryllium oxide from first principles.</article-title>
            <source>Nanotechnology</source>
            <year>2020</year>
            <month>Sep</month>
            <day>11</day>
            <volume>31</volume>
            <issue>37</issue>
            <fpage>375705</fpage>
            <pub-id pub-id-type="pmid">32470952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>The Burden of Trachea, Bronchus, and Lung Cancer Attributable to Occupational Exposure From 1990 to 2019.</article-title>
            <source>Front Public Health</source>
            <year>2022</year>
            <volume>10</volume>
            <fpage>928937</fpage>
            <pub-id pub-id-type="pmid">35784215</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <article-title>Beryllium and beryllium compounds.</article-title>
            <source>IARC Monogr Eval Carcinog Risks Hum</source>
            <year>1993</year>
            <volume>58</volume>
            <fpage>41</fpage>
            <page-range>41-117</page-range>
            <pub-id pub-id-type="pmid">8022058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boice</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Mumma</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Girardi</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Bellamy</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Dauer</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Samuels</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Eckerman</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Leggett</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Mortality among workers at the Los Alamos National Laboratory, 1943-2017.</article-title>
            <source>Int J Radiat Biol</source>
            <year>2022</year>
            <volume>98</volume>
            <issue>4</issue>
            <fpage>722</fpage>
            <page-range>722-749</page-range>
            <pub-id pub-id-type="pmid">34047625</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanderson</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Henneberger</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Martyny</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mroz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Beryllium contamination inside vehicles of machine shop workers.</article-title>
            <source>Appl Occup Environ Hyg</source>
            <year>1999</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-30</page-range>
            <pub-id pub-id-type="pmid">10457644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Islam</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Sanderson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Payne</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Naidu</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Desorption and Migration Behavior of Beryllium from Contaminated Soils: Insights for Risk-Based Management.</article-title>
            <source>ACS Omega</source>
            <year>2021</year>
            <month>Nov</month>
            <day>16</day>
            <volume>6</volume>
            <issue>45</issue>
            <fpage>30686</fpage>
            <page-range>30686-30697</page-range>
            <pub-id pub-id-type="pmid">34805696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cummings</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Stefaniak</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Virji</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A reconsideration of acute Beryllium disease.</article-title>
            <source>Environ Health Perspect</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>117</volume>
            <issue>8</issue>
            <fpage>1250</fpage>
            <page-range>1250-6</page-range>
            <pub-id pub-id-type="pmid">19672405</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Seay</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history.</article-title>
            <source>Am Rev Respir Dis</source>
            <year>1989</year>
            <month>Jun</month>
            <volume>139</volume>
            <issue>6</issue>
            <fpage>1479</fpage>
            <page-range>1479-86</page-range>
            <pub-id pub-id-type="pmid">2729754</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mroz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kreiss</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lezotte</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1991</year>
            <month>Jul</month>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">2071785</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fontenot</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Falta</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Freed</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Kotzin</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Identification of pathogenic T cells in patients with beryllium-induced lung disease.</article-title>
            <source>J Immunol</source>
            <year>1999</year>
            <month>Jul</month>
            <day>15</day>
            <volume>163</volume>
            <issue>2</issue>
            <fpage>1019</fpage>
            <page-range>1019-26</page-range>
            <pub-id pub-id-type="pmid">10395700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Crooks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mroz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>VanDyke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>McCanlies</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Virji</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rosenman</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Rossman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Monos</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fingerlin</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>HLA-DPB1 E69 genotype and exposure in beryllium sensitisation and disease.</article-title>
            <source>Occup Environ Med</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>120</fpage>
            <page-range>120-126</page-range>
            <pub-id pub-id-type="pmid">34535537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McKee</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Atif</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Falta</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Fontenot</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Innate and Adaptive Immunity in Noninfectious Granulomatous Lung Disease.</article-title>
            <source>J Immunol</source>
            <year>2022</year>
            <month>Apr</month>
            <day>15</day>
            <volume>208</volume>
            <issue>8</issue>
            <fpage>1835</fpage>
            <page-range>1835-1843</page-range>
            <pub-id pub-id-type="pmid">35418504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mayer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Hamzeh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Sarcoidosis and chronic beryllium disease: similarities and differences.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>316</fpage>
            <page-range>316-29</page-range>
            <pub-id pub-id-type="pmid">25007084</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Malo</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez-Escobar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Castrej&#x000f3;n-Ayala</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rojas</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>The Aggregation Pheromone of Metamasius spinolae (Coleoptera: Dryophthoridae) Revisited: Less is More.</article-title>
            <source>Environ Entomol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>20</day>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>803</fpage>
            <page-range>803-809</page-range>
            <pub-id pub-id-type="pmid">32457987</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Mroz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Balkissoon</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2005</year>
            <month>Jan</month>
            <day>01</day>
            <volume>171</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-60</page-range>
            <pub-id pub-id-type="pmid">15374840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Immunotoxicology of beryllium lung disease.</article-title>
            <source>Environ Health Prev Med</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>161</fpage>
            <page-range>161-4</page-range>
            <pub-id pub-id-type="pmid">21432059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saltini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Winestock</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kirby</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pinkston</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crystal</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells.</article-title>
            <source>N Engl J Med</source>
            <year>1989</year>
            <month>Apr</month>
            <day>27</day>
            <volume>320</volume>
            <issue>17</issue>
            <fpage>1103</fpage>
            <page-range>1103-9</page-range>
            <pub-id pub-id-type="pmid">2469014</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sawyer</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Fadok</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Chiarappa-Zucca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Fontenot</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Silveira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Beryllium-ferritin: lymphocyte proliferation and macrophage apoptosis in chronic beryllium disease.</article-title>
            <source>Am J Respir Cell Mol Biol</source>
            <year>2004</year>
            <month>Oct</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>470</fpage>
            <page-range>470-7</page-range>
            <pub-id pub-id-type="pmid">15256386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Petrovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tatum</surname>
                <given-names>OL</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Marrone</surname>
                <given-names>BL</given-names>
              </name>
            </person-group>
            <article-title>Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles.</article-title>
            <source>J Immunol</source>
            <year>1999</year>
            <month>Aug</month>
            <day>01</day>
            <volume>163</volume>
            <issue>3</issue>
            <fpage>1647</fpage>
            <page-range>1647-53</page-range>
            <pub-id pub-id-type="pmid">10415070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>McGrath</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lympany</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Welsh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Du Bois</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Silveira</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fontenot</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.</article-title>
            <source>J Immunol</source>
            <year>2003</year>
            <month>Dec</month>
            <day>15</day>
            <volume>171</volume>
            <issue>12</issue>
            <fpage>6910</fpage>
            <page-range>6910-8</page-range>
            <pub-id pub-id-type="pmid">14662898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <article-title>Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>160</volume>
            <issue>2</issue>
            <fpage>736</fpage>
            <page-range>736-55</page-range>
            <pub-id pub-id-type="pmid">10430755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VanORDSTRAND</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>HUGHES</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Beryllium poisoning.</article-title>
            <source>J Am Med Assoc</source>
            <year>1945</year>
            <month>Dec</month>
            <day>15</day>
            <volume>129</volume>
            <fpage>1084</fpage>
            <page-range>1084-90</page-range>
            <pub-id pub-id-type="pmid">21004768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <article-title>Beryllium skin granulomas from a broken fluorescent tube. By H.S. Van Ordstrand, E.W. Netherton, Joseph M. De Nardi, and Morris G. Carmody.</article-title>
            <source>Cleve Clin Q</source>
            <year>1983</year>
            <season>Summer</season>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>69</fpage>
            <page-range>69-72</page-range>
            <pub-id pub-id-type="pmid">6357549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stoeckle</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Chronic beryllium disease. Long-term follow-up of sixty cases and selective review of the literature.</article-title>
            <source>Am J Med</source>
            <year>1969</year>
            <month>Apr</month>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>545</fpage>
            <page-range>545-61</page-range>
            <pub-id pub-id-type="pmid">4892951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Significance of the blood beryllium lymphocyte proliferation test.</article-title>
            <source>Environ Health Perspect</source>
            <year>1996</year>
            <month>Oct</month>
            <volume>104 Suppl 5</volume>
            <issue>Suppl 5</issue>
            <fpage>953</fpage>
            <page-range>953-6</page-range>
            <pub-id pub-id-type="pmid">8933041</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>VAN ORDSTRAND</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Current concepts of beryllium poisoning.</article-title>
            <source>Ann Intern Med</source>
            <year>1951</year>
            <month>Dec</month>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>1203</fpage>
            <page-range>1203-17</page-range>
            <pub-id pub-id-type="pmid">14895001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eisenbud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lisson</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Epidemiological aspects of beryllium-induced nonmalignant lung disease: a 30-year update.</article-title>
            <source>J Occup Med</source>
            <year>1983</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>196</fpage>
            <page-range>196-202</page-range>
            <pub-id pub-id-type="pmid">6842310</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sprince</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Kazemi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Current (1975) problem of differentiating between beryllium disease and sarcoidosis.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>1976</year>
            <volume>278</volume>
            <fpage>654</fpage>
            <page-range>654-64</page-range>
            <pub-id pub-id-type="pmid">1067045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balmes</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Dweik</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Fireman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fontenot</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Muller-Quernheim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ostiguy</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pepper</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Saltini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuler</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Takaro</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Wambach</surname>
                <given-names>PF</given-names>
              </name>
              <collab>ATS Ad Hoc Committee on Beryllium Sensitivity and Chronic Beryllium Disease</collab>
            </person-group>
            <article-title>An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2014</year>
            <month>Nov</month>
            <day>15</day>
            <volume>190</volume>
            <issue>10</issue>
            <fpage>e34</fpage>
            <page-range>e34-59</page-range>
            <pub-id pub-id-type="pmid">25398119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beckett</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Cullen</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Variable response to long-term corticosteroid therapy in chronic beryllium disease.</article-title>
            <source>Chest</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>126</volume>
            <issue>6</issue>
            <fpage>2000</fpage>
            <page-range>2000-7</page-range>
            <pub-id pub-id-type="pmid">15596705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>HALL</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>WOOD</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>STOECKLE</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>TEPPER</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Case data from the beryllium registry.</article-title>
            <source>AMA Arch Ind Health</source>
            <year>1959</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-3</page-range>
            <pub-id pub-id-type="pmid">13616726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-147468.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Freiman</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Beryllium disease. The relation of pulmonary pathology to clinical course and prognosis based on a study of 130 cases from the U.S. beryllium case registry.</article-title>
            <source>Hum Pathol</source>
            <year>1970</year>
            <month>Mar</month>
            <volume>1</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-44</page-range>
            <pub-id pub-id-type="pmid">5521721</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
